{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,11,4]],"date-time":"2026-11-04T03:45:08Z","timestamp":1793763908868,"version":"4.6.1"},"reference-count":70,"publisher":"Elsevier BV","license":[{"start":{"date-parts":[[2022,2,1]],"date-time":"2022-02-01T00:00:00Z","timestamp":1643673600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2022,2,1]],"date-time":"2022-02-01T00:00:00Z","timestamp":1643673600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2021,12,2]],"date-time":"2021-12-02T00:00:00Z","timestamp":1638403200000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0\/"}],"content-domain":{"domain":["clinicalkey.com","clinicalkey.com.au","clinicalkey.es","clinicalkey.fr","clinicalkey.jp","em-consulte.com","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Biomedicine &amp; Pharmacotherapy"],"published-print":{"date-parts":[[2022,2]]},"DOI":"10.1016\/j.biopha.2021.112503","type":"journal-article","created":{"date-parts":[[2021,12,15]],"date-time":"2021-12-15T12:55:03Z","timestamp":1639572903000},"page":"112503","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":122,"special_numbering":"C","title":["Clinical implications of chemotherapeutic agent organ toxicity on perioperative care"],"prefix":"10.1016","volume":"146","author":[{"given":"Justin","family":"Zeien","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Wendy","family":"Qiu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Mason","family":"Triay","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Hemangini A.","family":"Dhaibar","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Diana","family":"Cruz-Topete","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Elyse M.","family":"Cornett","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ivan","family":"Urits","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Omar","family":"Viswanath","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Alan David","family":"Kaye","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"key":"10.1016\/j.biopha.2021.112503_bib1","unstructured":"World Health Organization. Cancer [Internet]. 2018 [cited 2020 Sep 8]. Available from: \u3008https:\/\/www.who.int\/news-room\/fact-sheets\/detail\/cancer\u3009."},{"key":"10.1016\/j.biopha.2021.112503_bib2","unstructured":"National Cancer Institute Surveillance E and ERP. Common Cancer Sites \u2014 Cancer Stat Facts [Internet]. [cited 2020 Sep 8]. Available from: \u3008https:\/\/seer.cancer.gov\/statfacts\/html\/common.html\u3009."},{"issue":"5","key":"10.1016\/j.biopha.2021.112503_bib3","first-page":"363","article-title":"Cancer treatment and survivorship statistics, 2019","volume":"69","author":"Miller","year":"2019","journal-title":"CA Cancer J. Clin."},{"key":"10.1016\/j.biopha.2021.112503_bib4","unstructured":"Division of Cancer Prevention and Control C for DC and P. Information for Health Care Providers | Preventing Infections in Cancer Patients | CDC [Internet]. [cited 2020 Sep 8]. Available from: \u3008https:\/\/www.cdc.gov\/cancer\/preventinfections\/providers.htm\u3009."},{"issue":"1","key":"10.1016\/j.biopha.2021.112503_bib5","doi-asserted-by":"crossref","first-page":"167","DOI":"10.1016\/j.emc.2013.09.002","article-title":"An approach to chemotherapy-associated toxicity","volume":"32","author":"Livshits","year":"2014","journal-title":"Emerg. Med Clin. North Am."},{"key":"10.1016\/j.biopha.2021.112503_bib6","series-title":"Principles of Critical Care","article-title":"Chapter 95: toxicities of chemotherapy","author":"Hale","year":"2015"},{"issue":"2","key":"10.1016\/j.biopha.2021.112503_bib7","first-page":"121","article-title":"Anaesthetic challenges in cancer patients: current therapies and pain management","volume":"24","author":"Gudaityt\u0117","year":"2017","journal-title":"Acta Med. Litu."},{"key":"10.1016\/j.biopha.2021.112503_bib8","unstructured":"Common Toxicities of Chemotherapy [Internet]. [cited 2020 Sep 8]. Available from: \u3008https:\/\/www1.cgmh.org.tw\/intr\/intr5\/c6700\/OBGYN\/f\/web\/ChemotherapyToxicity\/index.htm\u3009."},{"issue":"1","key":"10.1016\/j.biopha.2021.112503_bib9","first-page":"18","article-title":"Anticancer chemotherapy and it\u2019s anaesthetic implications (current concepts)","volume":"53","author":"Gehdoo","year":"2009","journal-title":"Indian J. Anaesth."},{"issue":"3","key":"10.1016\/j.biopha.2021.112503_bib10","first-page":"219","article-title":"Anesthetic implications for cancer chemotherapy","volume":"75","author":"Maracic","year":"2007","journal-title":"AANA J."},{"issue":"5 SUPPL.","key":"10.1016\/j.biopha.2021.112503_bib11","doi-asserted-by":"crossref","first-page":"165S","DOI":"10.1378\/chest.115.suppl_2.165S","article-title":"Perioperative management of the patient with cancer","volume":"115","author":"Lefor","year":"1999","journal-title":"Chest"},{"issue":"6","key":"10.1016\/j.biopha.2021.112503_bib12","doi-asserted-by":"crossref","first-page":"478","DOI":"10.1002\/ssu.2980090605","article-title":"Anesthesia considerations for pediatric cancer","volume":"9","author":"McDowall","year":"1993","journal-title":"Semin Surg. Oncol."},{"key":"10.1016\/j.biopha.2021.112503_bib13","doi-asserted-by":"crossref","first-page":"859","DOI":"10.1097\/00003643-200311000-00002","article-title":"Anaesthetic implications of anticancer chemotherapy","volume":"20","author":"Kvolik","year":"2003","journal-title":"Eur. J. Anaesthesiol."},{"issue":"23","key":"10.1016\/j.biopha.2021.112503_bib14","doi-asserted-by":"crossref","first-page":"2749","DOI":"10.1161\/CIRCULATIONAHA.112.100560","article-title":"Cancer therapy-induced cardiac toxicity in early breast cancer addressing the unresolved issues","volume":"126","author":"Khouri","year":"2012","journal-title":"Circulation"},{"issue":"5","key":"10.1016\/j.biopha.2021.112503_bib15","doi-asserted-by":"crossref","first-page":"362","DOI":"10.1007\/s11886-013-0362-6","article-title":"Cardiac toxicity of anticancer agents","volume":"15","author":"Colombo","year":"2013","journal-title":"Curr. Cardiol. Rep."},{"issue":"3","key":"10.1016\/j.biopha.2021.112503_bib16","doi-asserted-by":"crossref","first-page":"307","DOI":"10.1097\/01.aco.0000169240.14056.19","article-title":"Anaesthesia and anti-cancer chemotherapeutic drugs","volume":"18","author":"Huettemann","year":"2005","journal-title":"Curr. Opin. Anaesthesiol."},{"issue":"23","key":"10.1016\/j.biopha.2021.112503_bib17","doi-asserted-by":"crossref","first-page":"2474","DOI":"10.1161\/CIRCULATIONAHA.106.635144","article-title":"Prevention of high-dose chemotherapy-induced cardiotoxicity in high-risk patients by angiotensin-converting enzyme inhibition","volume":"114","author":"Cardinale","year":"2006","journal-title":"Circulation"},{"issue":"11","key":"10.1016\/j.biopha.2021.112503_bib18","doi-asserted-by":"crossref","first-page":"2258","DOI":"10.1016\/j.jacc.2006.07.052","article-title":"Protective effects of carvedilol against anthracycline-induced cardiomyopathy","volume":"48","author":"Kalay","year":"2006","journal-title":"J. Am. Coll. Cardiol."},{"key":"10.1016\/j.biopha.2021.112503_bib19","doi-asserted-by":"crossref","DOI":"10.1155\/2012\/713294","article-title":"Strategies to prevent anthracycline-related congestive heart failure in survivors of childhood cancer","volume":"2012","author":"Armenian","year":"2012","journal-title":"Cardiol. Res Pract."},{"issue":"3","key":"10.1016\/j.biopha.2021.112503_bib20","first-page":"624","article-title":"Bleomycin and hyperoxia exposure in the operating room","volume":"81","author":"Mathes","year":"1995","journal-title":"Anesth. Analg."},{"issue":"1","key":"10.1016\/j.biopha.2021.112503_bib21","doi-asserted-by":"crossref","first-page":"66","DOI":"10.1097\/00003643-199901000-00013","article-title":"Intraoperative respiratory failure in a patient after treatment with bleomycin: previous and current intraoperative exposure to 50% oxygen","volume":"16","author":"Luis","year":"1999","journal-title":"Eur. J. Anaesthesiol."},{"issue":"5","key":"10.1016\/j.biopha.2021.112503_bib22","first-page":"586","article-title":"Chemotherapy induced cardiovascular toxicity: beyond anthracyclines","volume":"80","author":"Ai","year":"2014","journal-title":"Minerva Anestesiol."},{"issue":"22","key":"10.1016\/j.biopha.2021.112503_bib23","doi-asserted-by":"crossref","first-page":"e77","DOI":"10.1016\/j.jacc.2014.07.944","article-title":"ACC\/AHA guideline on perioperative cardiovascular evaluation and management of patients undergoing noncardiac surgery: a report of the American college of cardiology\/American heart association task force on practice guidelines","volume":"64","author":"Fleisher","year":"2014","journal-title":"J. Am. Coll. Cardiol."},{"issue":"1","key":"10.1016\/j.biopha.2021.112503_bib24","doi-asserted-by":"crossref","first-page":"163","DOI":"10.1016\/S0022-5347(17)51014-9","article-title":"Risk factors of anesthesia and surgery in bleomycin-treated patients","volume":"130","author":"Hulbert","year":"1983","journal-title":"J. Urol."},{"issue":"2","key":"10.1016\/j.biopha.2021.112503_bib25","doi-asserted-by":"crossref","first-page":"173","DOI":"10.1016\/S0025-6196(12)60489-3","article-title":"Oxygen-exacerbated bleomycin pulmonary toxicity","volume":"66","author":"Ingrassia","year":"1991","journal-title":"Mayo Clin. Proc."},{"key":"10.1016\/j.biopha.2021.112503_bib26","first-page":"182","article-title":"Anesthetic implications for chemotherapy","volume":"9","author":"Rubin","year":"1987","journal-title":"Curr. Rev. Nurse Anesth."},{"issue":"9","key":"10.1016\/j.biopha.2021.112503_bib27","doi-asserted-by":"crossref","first-page":"1916","DOI":"10.1002\/cncr.20983","article-title":"Incidence, cost, and mortality of neutropenia hospitalization associated with chemotherapy","volume":"103","author":"Caggiano","year":"2005","journal-title":"Cancer"},{"issue":"2","key":"10.1016\/j.biopha.2021.112503_bib28","doi-asserted-by":"crossref","first-page":"149","DOI":"10.1007\/BF03010041","article-title":"Perioperative complications in patients with anthracycline chemotherapeutic agents","volume":"32","author":"Burrows","year":"1985","journal-title":"Can. Anaesth. Soc. J."},{"issue":"2","key":"10.1016\/j.biopha.2021.112503_bib29","doi-asserted-by":"crossref","first-page":"435","DOI":"10.1002\/1097-0142(19910715)68:2<435::AID-CNCR2820680237>3.0.CO;2-#","article-title":"Exercise echocardiography in the detection of anthracycline cardiotoxicity","volume":"68","author":"Weesner","year":"1991","journal-title":"Cancer"},{"issue":"3","key":"10.1016\/j.biopha.2021.112503_bib30","doi-asserted-by":"crossref","first-page":"273","DOI":"10.1016\/0167-5273(92)90024-W","article-title":"Cardiac complications of intensive dose mitoxantrone and cyclophosphamide with autologous bone marrow transplantation in metastatic breast cancer","volume":"34","author":"Lewkow","year":"1992","journal-title":"Int. J. Cardiol."},{"issue":"6","key":"10.1016\/j.biopha.2021.112503_bib31","first-page":"873","article-title":"Clinical spectrum of anthracycline antibiotic cardiotoxicity","volume":"62","author":"Bristow","year":"1978","journal-title":"Cancer Treat. Rep."},{"issue":"5","key":"10.1016\/j.biopha.2021.112503_bib32","doi-asserted-by":"crossref","first-page":"710","DOI":"10.7326\/0003-4819-91-5-710","article-title":"Risk factors for doxorubicin-induced congestive heart failure","volume":"91","author":"Von Hoff","year":"1979","journal-title":"Ann. Intern. Med."},{"issue":"4","key":"10.1016\/j.biopha.2021.112503_bib33","doi-asserted-by":"crossref","first-page":"941","DOI":"10.1213\/01.ANE.0000108135.52036.48","article-title":"The influence of anthracycline therapy on cardiac function during anesthesia","volume":"98","author":"Huettemann","year":"2004","journal-title":"Anesth. Analg."},{"issue":"6","key":"10.1016\/j.biopha.2021.112503_bib34","first-page":"461","article-title":"Review of tests for monitoring doxorubicin-induced cardiomyopathy","volume":"53","author":"Ganz","year":"1996","journal-title":"Oncology"},{"issue":"10","key":"10.1016\/j.biopha.2021.112503_bib35","doi-asserted-by":"crossref","first-page":"539","DOI":"10.1016\/S1010-7940(05)80001-6","article-title":"Respiratory complications after surgical treatment of esophageal cancer. A study of 309 patients according to the type of resection","volume":"9","author":"Dumont","year":"1995","journal-title":"Eur. J. Cardio Thorac. Surg. J. Eur. Assoc. Cardio Thorac. Surg."},{"issue":"4","key":"10.1016\/j.biopha.2021.112503_bib36","doi-asserted-by":"crossref","first-page":"993","DOI":"10.1378\/chest.99.4.993","article-title":"Perioperative considerations for patients treated with bleomycin","volume":"99","author":"Waid-Jones","year":"1991","journal-title":"Chest"},{"issue":"6128","key":"10.1016\/j.biopha.2021.112503_bib37","doi-asserted-by":"crossref","first-page":"1664","DOI":"10.1136\/bmj.1.6128.1664","article-title":"Factors influencing postoperative morbidity and mortality in patients treated with bleomycin","volume":"1","author":"Goldiner","year":"1978","journal-title":"Br. Med. J."},{"issue":"1","key":"10.1016\/j.biopha.2021.112503_bib38","first-page":"121","article-title":"The hazards of anesthesia and surgery in bleomycin-treated patients","volume":"6","author":"Goldiner","year":"1979","journal-title":"Semin Oncol."},{"issue":"4","key":"10.1016\/j.biopha.2021.112503_bib39","doi-asserted-by":"crossref","first-page":"1347","DOI":"10.1016\/S0022-5347(01)62533-3","article-title":"Bleomycin associated pulmonary toxicity: is perioperative oxygen restriction necessary?","volume":"160","author":"Donat","year":"1998","journal-title":"J. Urol."},{"issue":"2","key":"10.1016\/j.biopha.2021.112503_bib40","doi-asserted-by":"crossref","first-page":"307","DOI":"10.1016\/0002-9343(78)90825-2","article-title":"Platinum nephrotoxicity","volume":"65","author":"Madias","year":"1978","journal-title":"Am. J. Med."},{"issue":"10","key":"10.1016\/j.biopha.2021.112503_bib41","doi-asserted-by":"crossref","first-page":"2214","DOI":"10.1002\/1097-0142(19861115)58:10<2214::AID-CNCR2820581009>3.0.CO;2-I","article-title":"The long-term effect of cisplatin on renal function","volume":"58","author":"Fjeldborg","year":"1986","journal-title":"Cancer"},{"issue":"2","key":"10.1016\/j.biopha.2021.112503_bib42","doi-asserted-by":"crossref","first-page":"75","DOI":"10.1056\/NEJM197407112910205","article-title":"Neurotoxicity of commonly used antineoplastic agents (first of two parts)","volume":"291","author":"Weiss","year":"1974","journal-title":"N. Engl. J. Med."},{"issue":"5","key":"10.1016\/j.biopha.2021.112503_bib43","first-page":"819","article-title":"Peripheral neuropathy as a complication of cis-dichlorodiammineplatinum(II) treatment: a case report","volume":"62","author":"Kedar","year":"1978","journal-title":"Cancer Treat. Rep."},{"issue":"5","key":"10.1016\/j.biopha.2021.112503_bib44","first-page":"551","article-title":"Chemotherapeutic agents and hepatotoxicity","volume":"19","author":"Perry","year":"1992","journal-title":"Semin. Oncol."},{"issue":"7","key":"10.1016\/j.biopha.2021.112503_bib45","doi-asserted-by":"crossref","first-page":"1531","DOI":"10.1002\/cncr.11671","article-title":"The burdens of cancer therapy. Clinical and economic outcomes of chemotherapy-induced mucositis","volume":"98","author":"Elting","year":"2003","journal-title":"Cancer"},{"key":"10.1016\/j.biopha.2021.112503_bib46","unstructured":"NDA\/BLA Multi-disciplinary Review and Evaluation NDA 212608 AYVAKIT (avapritinib) [Internet]. 2018 [cited 2021 Nov 29] p. 186. Available from: \u3008https:\/\/www.accessdata.fda.gov\/drugsatfda_docs\/nda\/2020\/212608Orig1s000MultidisciplineR.pdf\u3009."},{"key":"10.1016\/j.biopha.2021.112503_bib47","unstructured":"QINLOCKTM (ripretinib) tablets, for oral use [Internet]. 2020 [cited 2021 Nov 29]. Report No.: Reference ID: 4609421. Available from: \u3008https:\/\/www.accessdata.fda.gov\/drugsatfda_docs\/label\/2020\/213973s000lbl.pdf\u3009."},{"key":"10.1016\/j.biopha.2021.112503_bib48","unstructured":"TAZVERIK (tazemetostat) tablets, for oral use [Internet]. 2020. Report No.: Reference ID: 4627347. Available from: \u3008https:\/\/www.accessdata.fda.gov\/drugsatfda_docs\/label\/2020\/213400s000lbl.pdf\u3009."},{"key":"10.1016\/j.biopha.2021.112503_bib49","unstructured":"SARCLISA\u00ae (isatuximab-irfc) injection, for intravenous use [Internet]. 2020. Report No.: Reference ID: 4568826. Available from: \u3008https:\/\/www.accessdata.fda.gov\/drugsatfda_docs\/label\/2020\/761113s000lbl.pdf\u3009."},{"key":"10.1016\/j.biopha.2021.112503_bib50","unstructured":"TUKYSATM (tucatinib) tablets, for oral use [Internet]. 2020. Report No.: Reference ID: 4593756. Available from: \u3008https:\/\/www.accessdata.fda.gov\/drugsatfda_docs\/label\/2020\/213411s000lbl.pdf\u3009."},{"key":"10.1016\/j.biopha.2021.112503_bib51","unstructured":"TRODELVY\u00ae (sacituzumab govitecan-hziy) for injection, for intravenous use [Internet]. 2020. Report No.: Reference ID: 4778226. Available from: \u3008https:\/\/www.accessdata.fda.gov\/drugsatfda_docs\/label\/2021\/761115s009lbl.pdf\u3009."},{"key":"10.1016\/j.biopha.2021.112503_bib52","unstructured":"PEMAZYRETM (pemigatinib) tablets, for oral use [Internet]. 2020. Report No.: Reference ID: 4591160. Available from: \u3008https:\/\/www.accessdata.fda.gov\/drugsatfda_docs\/label\/2020\/213736s000lbl.pdf\u3009."},{"key":"10.1016\/j.biopha.2021.112503_bib53","unstructured":"TABRECTATM (capmatinib) tablets, for oral use [Internet]. Report No.: Reference ID: 4603951. Available from: \u3008https:\/\/www.accessdata.fda.gov\/drugsatfda_docs\/label\/2020\/213591s000lbl.pdf\u3009."},{"key":"10.1016\/j.biopha.2021.112503_bib54","doi-asserted-by":"crossref","first-page":"515","DOI":"10.2147\/JPR.S97759","article-title":"Effectiveness of the World Health Organization cancer pain relief guidelines: an integrative review","volume":"9","author":"Carlson","year":"2016","journal-title":"J. Pain. Res. Dove Med. Press Ltd"},{"issue":"3","key":"10.1016\/j.biopha.2021.112503_bib55","first-page":"182","article-title":"Optimal pain management for patients with cancer in the modern era","volume":"68","author":"Scarborough","year":"2018","journal-title":"CA Cancer J. Clin."},{"issue":"2","key":"10.1016\/j.biopha.2021.112503_bib56","first-page":"121","article-title":"Anaesthetic challenges in cancer patients: current therapies and pain management","volume":"24","author":"Gudaityt\u0117","year":"2017","journal-title":"Acta Med. Litu."},{"issue":"4","key":"10.1016\/j.biopha.2021.112503_bib57","doi-asserted-by":"crossref","first-page":"443","DOI":"10.3390\/cancers11040443","article-title":"Interventional techniques to management of cancer-related pain: clinical and critical aspects","volume":"11","author":"Kurita","year":"2019","journal-title":"Cancers"},{"issue":"6","key":"10.1016\/j.biopha.2021.112503_bib58","doi-asserted-by":"crossref","first-page":"924","DOI":"10.1093\/ndt\/gfw338","article-title":"Nephrotoxicity of anticancer treatment","volume":"32","author":"Ma\u0142yszko","year":"2017","journal-title":"Nephrol. Dial. Transpl."},{"issue":"5","key":"10.1016\/j.biopha.2021.112503_bib59","doi-asserted-by":"crossref","first-page":"688","DOI":"10.1093\/ckj\/sfx080","article-title":"Update on pain management in patients with chronic kidney disease","volume":"10","author":"Pham","year":"2017","journal-title":"Clin. Kidney J."},{"issue":"3","key":"10.1016\/j.biopha.2021.112503_bib60","doi-asserted-by":"crossref","first-page":"317","DOI":"10.3350\/cmh.2014.20.3.317","article-title":"Chemotherapy induced liver abnormalities: an imaging perspective","volume":"20","author":"Sharma","year":"2014","journal-title":"Clin. Mol. Hepatol."},{"key":"10.1016\/j.biopha.2021.112503_bib61","doi-asserted-by":"crossref","first-page":"1645","DOI":"10.2165\/11635500-000000000-00000","article-title":"Analgesics in patients with hepatic impairment: pharmacology and clinical implications","volume":"72","author":"Bosilkovska","year":"2012","journal-title":"Drugs"},{"key":"10.1016\/j.biopha.2021.112503_bib62","first-page":"135","article-title":"Pain management in patients with cirrhosis","volume":"vol. 11","author":"Rakoski","year":"2018"},{"key":"10.1016\/j.biopha.2021.112503_bib63","article-title":"Opioid drugs in patients with liver disease: a systematic review","volume":"Vol. 16","author":"Soleimanpour","year":"2016","journal-title":"Hepat. Mon. Kowsar Med. Publ. Co."},{"issue":"3","key":"10.1016\/j.biopha.2021.112503_bib64","doi-asserted-by":"crossref","first-page":"311","DOI":"10.1177\/0310057X0503300306","article-title":"Acute pain management pharmacology for the patient with concurrent renal or hepatic disease","volume":"33","author":"Murphy","year":"2005","journal-title":"Anaesth. Intensive Care"},{"key":"10.1016\/j.biopha.2021.112503_bib65","first-page":"3","article-title":"Cardiotoxicity following cancer treatment","volume":"86","author":"Walls","year":"2017","journal-title":"Ulst. Med. J. Ulst. Med. Soc."},{"issue":"6","key":"10.1016\/j.biopha.2021.112503_bib66","first-page":"75","article-title":"Pain in heart failure patients. support care","volume":"19","author":"Wingate","year":"2011","journal-title":"Heart Fail"},{"key":"10.1016\/j.biopha.2021.112503_bib67","doi-asserted-by":"crossref","first-page":"143","DOI":"10.1517\/17425255.2014.856881","article-title":"Assessment of nonsteroidal anti-inflammatory drug-induced cardiotoxicity","volume":"10","author":"Singh","year":"2014","journal-title":"Expert Opin. Drug Metab. Toxicol. Expert Opin. Drug Metab. Toxicol."},{"key":"10.1016\/j.biopha.2021.112503_bib68","doi-asserted-by":"crossref","first-page":"401","DOI":"10.1159\/000492616","article-title":"Opioids and cardiac arrhythmia: a literature review","volume":"27","author":"Behzadi","year":"2018","journal-title":"Med. Princ. Pract."},{"key":"10.1016\/j.biopha.2021.112503_bib69","doi-asserted-by":"crossref","first-page":"46","DOI":"10.1016\/j.ejphar.2018.04.009","article-title":"Effects of propofol on cancer development and chemotherapy: potential mechanisms","volume":"831","author":"Jiang","year":"2018","journal-title":"Eur. J. Pharm."},{"issue":"1","key":"10.1016\/j.biopha.2021.112503_bib70","doi-asserted-by":"crossref","first-page":"159","DOI":"10.1007\/s10555-016-9647-8","article-title":"Anesthetic technique and cancer recurrence in oncologic surgery: unraveling the puzzle","volume":"36","author":"Kim","year":"2017","journal-title":"Cancer Metastasis Rev."}],"container-title":["Biomedicine &amp; Pharmacotherapy"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0753332221012890?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0753332221012890?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2026,5,28]],"date-time":"2026-05-28T10:53:10Z","timestamp":1779965590000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0753332221012890"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2022,2]]},"references-count":70,"alternative-id":["S0753332221012890"],"URL":"https:\/\/doi.org\/10.1016\/j.biopha.2021.112503","relation":{},"ISSN":["0753-3322"],"issn-type":[{"value":"0753-3322","type":"print"}],"subject":[],"published":{"date-parts":[[2022,2]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Clinical implications of chemotherapeutic agent organ toxicity on perioperative care","name":"articletitle","label":"Article Title"},{"value":"Biomedicine & Pharmacotherapy","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.biopha.2021.112503","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"Published by Elsevier Masson SAS.","name":"copyright","label":"Copyright"}],"article-number":"112503"}}